HF
NGM

HRT Financial’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

HRT Financial’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,821
Closed -$11K – 3326
2023
Q4 		$11K Buy
+12,821
New +$11.3K ﹤0.01% 2080
2023
Q3 		– Sell
-102,439
Closed -$265K – 3314
2023
Q2 		$265K Sell
102,439
-22,465
-18% -$80.1K ﹤0.01% 1705
2023
Q1 		$509K Buy
+124,904
New +$577K 0.01% 1372
2021
Q3 		– Sell
-97,313
Closed -$1.92M – 3895
2021
Q2 		$1.92M Buy
+97,313
New +$2.28M 0.02% 645

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HRT Financial's NGM Position: Q1 2024 in Review

HRT Financial sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 12,821 shares — an estimated $11K sold.

HRT Financial first reported a position in NGM in Q2 2021 and held it in 4 quarters. The position peaked at $1.92M in Q2 2021. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • HRT Financial reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • HRT Financial sold 12,821 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $11K.
  • HRT Financial first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • HRT Financial's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.92M in Q2 2021.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on HRT Financial's 13F filing for Q1 2024, filed 13 May 2024.